Literature DB >> 17201727

Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat.

Sarah Bigham, Christopher McGuigan, Bridget K MacDonald.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17201727     DOI: 10.1111/j.1528-1167.2006.00945_1.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


× No keyword cloud information.
  3 in total

Review 1.  Orlistat-associated adverse effects and drug interactions: a critical review.

Authors:  Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 2.  Benefit-risk assessment of orlistat in the treatment of obesity.

Authors:  Priya Sumithran; Joseph Proietto
Journal:  Drug Saf       Date:  2014-08       Impact factor: 5.606

Review 3.  Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.